Analytics, not advice. Rankings and scores describe past performance and are not recommendations.
Uncategorised
NIPPON INDIA PHARMA FUND - DIRECT Plan - IDCW Option
Nippon India Mutual Fund
32slipping
Latest NAV
₹175.6974
as of 07 Aug 2026
AUM
—
Expense ratio
—
Inception
14 May 2026
FundScore
32/100slipping
Rank #686 of 1007 · top 68%
A daily percentile of this fund’s past performance within its SEBI category — analytics, not advice, and not a prediction or recommendation.
Trailing returns
Annualised returns to the latest NAV. Refreshed nightly.
1M
2.87%
3M
6.40%
6M
15.58%
1Y
5.45%
3Y CAGR
10.18%
5Y CAGR
8.12%
Since incep.
10.13%
NAV history
Zoom and pan · ranges from 1M to since-inception.
Rolling returns
Every 30-day step. The true distribution, not cherry-picked.
Rank history
Percentile within category over the last 2 years.
FundScore components
Pro-only breakdown of consistency, recency, and volatility scores.
Upgrade to Pro to see the raw drivers behind this scheme's FundScore label.
Pro
Market-cap distribution
Large / mid / small / micro-cap split of this fund's equity holdings, from its latest look-through portfolio. Shown as a share of classified equity.
Large cap41.0%
Mid cap29.3%
Small cap29.6%
Stock holdings
Latest portfolio disclosure for this scheme. Snapshot as of 31 May 2026.
Sun Pharmaceutical Industries Limited
equity
13.35%
Lupin Limited
equity
7.31%
Dr. Reddy's Laboratories Limited
equity
6.72%
Cipla Limited
equity
6.16%
Divi's Laboratories Limited
equity
5.80%
Apollo Hospitals Enterprise Limited
equity
5.20%
Mankind Pharma Limited
equity
3.94%
MedPlus Health Services Limited
equity
3.68%
Sai Life Sciences Limited
equity
3.43%
Vijaya Diagnostic Centre Limited
equity
3.21%
Ajanta Pharma Limited
equity
3.21%
Max Healthcare Institute Limited
equity
2.97%
Thyrocare Technologies Limited
equity
2.56%
IPCA Laboratories Limited
equity
2.41%
GlaxoSmithKline Pharmaceuticals Limited
equity
2.34%
Aurobindo Pharma Limited
equity
2.32%
Abbott India Limited
equity
2.31%
Gland Pharma Limited
equity
2.09%
Alkem Laboratories Limited
equity
2.06%
Dr. Lal Path Labs Limited
equity
1.90%
Narayana Hrudayalaya Limited
equity
1.81%
Syngene International Limited
equity
1.79%
Pfizer Limited
equity
1.69%
Emcure Pharmaceuticals Limited
equity
1.47%
Suraksha Diagnostic Limited
equity
1.29%
Fortis Healthcare Limited
equity
1.19%
Sanofi Consumer Healthcare India Limited
equity
1.14%
Anthem Biosciences Limited
equity
0.93%
Akums Drugs and Pharmaceuticals Limited
equity
0.92%
Sanofi India Limited
equity
0.83%